Views & Analysis The best-selling drugs of the next 5 years Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling dru
News Merck claims a brace of head and neck cancer approvals Merck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals for Keytruda in newly diagnosed patients on the same day.
News FDA names a new CDER director, choosing a biotech vet The FDA has rounded out its senior leadership by naming biopharma industry executive George Tidmarsh to the role of CDER director.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
